title: New liposomal doxorubicin nanoformulation for osteosarcoma: Drug release kinetic study based on thermo and pH sensitivity.
abstract: A novel approach was developed for the preparation of stealth controlled-release liposomal doxorubicin. Various liposomal formulations were prepared by employing both thin film and pH gradient hydration techniques. The optimum formulation contained phospholipid and cholesterol in 1:0.43 molar ratios in the presence of 3% DSPE-mPEG (2000). The liposomal formulation was evaluated by determining mean size of vesicle, encapsulation efficiency, polydispersity index, zeta potentials, carrier's functionalization, and surface morphology. The vesicle size, encapsulation efficiency, polydispersity index, and zeta potentials of purposed formula were 93.61 nm, 82.8%, 0.14, and -23, respectively. Vesicles were round-shaped and smooth-surfaced entities with sharp boundaries. In addition, two colorimetric methods for cytotoxicity assay were compared and the IC50(the half maximal inhibitory concentration) of both methods for encapsulated doxorubicin was determined to be 0.1 μg/ml. The results of kinetic drug release were investigated at several different temperatures and pH levels, which showed that purposed formulation was thermo and pH sensitive.
authors.affiliation: Department of Life Science Engineering, Faculty of New Sciences & Technologies, University of Tehran, Tehran, Iran.|Department of Nano Biotechnology, Research Center for New Technologies in Life Science Engineering, University of Tehran, Tehran, Iran.
authors.forename: Fateme
authors.identifier: http://orcid.org/0000-0002-8655-2118
authors.initials: F
authors.lastname: Haghiralsadat
authors.affiliation: Department of Nano Biotechnology, Research Center for New Technologies in Life Science Engineering, University of Tehran, Tehran, Iran.|Department of Biotechnology and Pharmaceutical Engineering, School of Engineering, University of Tehran, Tehran, Iran.|Department of Oral & Maxillofacial Surgery, VU University Medical Center, MOVE Research Institute Amsterdam, Amsterdam, The Netherlands.
authors.forename: Ghasem
authors.initials: G
authors.lastname: Amoabediny
authors.affiliation: Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.|Biotechnology Research Center, International Campus, Shahid Sadoughi University of Medical Science, Yazd, Iran.
authors.forename: Mohammad Hasan
authors.initials: MH
authors.lastname: Sheikhha
authors.affiliation: Department of Orthopedic Surgery, VU University Medical Center, MOVE Research Institute, Amsterdam, Netherlands.|Oral Cell Biology and Functional Anatomy, VU University, Amsterdam, North Holland, Netherlands.
authors.forename: Behrouz
authors.initials: B
authors.lastname: Zandieh-Doulabi
authors.affiliation: Department of Nano Biotechnology, Research Center for New Technologies in Life Science Engineering, University of Tehran, Tehran, Iran.|Department of Biotechnology and Pharmaceutical Engineering, School of Engineering, University of Tehran, Tehran, Iran.
authors.forename: Samira
authors.initials: S
authors.lastname: Naderinezhad
authors.affiliation: Department of Oral & Maxillofacial Surgery, VU University Medical Center, MOVE Research Institute Amsterdam, Amsterdam, The Netherlands.|Department of Orthopedic Surgery, VU University Medical Center, MOVE Research Institute, Amsterdam, Netherlands.
authors.forename: Marco N
authors.initials: MN
authors.lastname: Helder
authors.affiliation: Department of Oral & Maxillofacial Surgery, VU University Medical Center, MOVE Research Institute Amsterdam, Amsterdam, The Netherlands.
authors.forename: Tymour
authors.initials: T
authors.lastname: Forouzanfar
mesh_terms: D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002784:Cholesterol / Q000737:chemistry; D004317:Doxorubicin / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D004339:Drug Compounding; D065546:Drug Liberation; D004355:Drug Stability; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008081:Liposomes / Q000737:chemistry*; D049329:Nanostructures / Q000737:chemistry*; D010006:Osteoblasts / Q000166:cytology / Q000378:metabolism; D012516:Osteosarcoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010316:Particle Size; D010743:Phospholipids / Q000737:chemistry; D013696:Temperature
chemical_list: D008081:Liposomes; D010743:Phospholipids; D004317:Doxorubicin; D002784:Cholesterol
keywords: cytotoxicity; drug delivery; liposome characterization; osteosarcoma; release kinetics